Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1958 1
1959 1
1961 2
1962 3
1963 1
1964 4
1965 11
1966 3
1967 3
1968 2
1969 3
1972 1
1974 1
1975 2
1976 2
1977 9
1978 6
1979 3
1980 9
1981 8
1982 4
1983 1
1984 5
1985 3
1986 2
1987 2
1988 3
1989 5
1990 5
1991 3
1992 2
1993 4
1994 8
1995 8
1996 5
1997 6
1998 1
1999 10
2000 4
2001 5
2002 6
2003 7
2004 17
2005 6
2006 9
2007 8
2008 6
2009 2
2010 7
2011 16
2012 11
2013 25
2014 23
2015 20
2016 15
2017 38
2018 25
2019 39
2020 32
2021 29
2022 28
2023 25

Text availability

Article attribute

Article type

Publication date

Search Results

525 results

Results by year

Filters applied: . Clear all
Page 1
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Among authors: pineda al. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Free article. Clinical Trial.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Bonaca MP, et al. Among authors: pineda al. Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133605 Free article. Clinical Trial.
Cranial nerve 13.
Pineda AG, Leon-Sarmiento FE, Doty RL. Pineda AG, et al. Handb Clin Neurol. 2019;164:135-144. doi: 10.1016/B978-0-444-63855-7.00009-5. Handb Clin Neurol. 2019. PMID: 31604543 Review.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Sabatine MS, et al. Among authors: pineda al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15. Lancet Diabetes Endocrinol. 2017. PMID: 28927706 Free article. Clinical Trial.
ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines.
Preston CG, Wright MW, Madhavrao R, Harrison SM, Goldstein JL, Luo X, Wand H, Wulf B, Cheung G, Mandell ME, Tong H, Cheng S, Iacocca MA, Pineda AL, Popejoy AB, Dalton K, Zhen J, Dwight SS, Babb L, DiStefano M, O'Daniel JM, Lee K, Riggs ER, Zastrow DB, Mester JL, Ritter DI, Patel RY, Subramanian SL, Milosavljevic A, Berg JS, Rehm HL, Plon SE, Cherry JM, Bustamante CD, Costa HA; Clinical Genome Resource (ClinGen). Preston CG, et al. Among authors: pineda al. Genome Med. 2022 Jan 18;14(1):6. doi: 10.1186/s13073-021-01004-8. Genome Med. 2022. PMID: 35039090 Free PMC article.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP; FOURIER Steering Committee and Investigators. Charytan DM, et al. Among authors: pineda al. J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513. J Am Coll Cardiol. 2019. PMID: 31196453 Free article. Clinical Trial.
Intraoperative blood salvage.
Pineda AA, Valbonesi M. Pineda AA, et al. Baillieres Clin Haematol. 1990 Apr;3(2):385-403. doi: 10.1016/s0950-3536(05)80056-3. Baillieres Clin Haematol. 1990. PMID: 2224154 Review.
Software Training in HEP.
Malik S, Meehan S, Lieret K, Oan Evans M, Villanueva MH, Katz DS, Stewart GA, Elmer P, Aziz S, Bellis M, Bianchi RM, Bianco G, Bonilla JS, Burger A, Burzynski J, Chamont D, Feickert M, Gadow P, Gruber BM, Guest D, Hageboeck S, Heinrich L, Horzela MM, Huwiler M, Lange C, Lehmann K, Li K, Majumder D, Mamužić J, Nelson K, Newhouse R, Nibigira E, Norberg S, Pineda AS, Proffitt M, Regnery B, Roepe A, Roiser S, Schreiner H, Shadura O, Stark G, Swatman SN, Thais S, Valassi A, Wunsch S, Yakobovitch D, Yuan S. Malik S, et al. Among authors: pineda as. Comput Softw Big Sci. 2021;5(1):22. doi: 10.1007/s41781-021-00069-9. Epub 2021 Oct 8. Comput Softw Big Sci. 2021. PMID: 34642648 Free PMC article.
525 results